|
|
|
|
|
Bumetanide
drug data and news
Bumetanide drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Bumetanide | ||
| Brand Names/Synonyms | B3023; Bumetanida [Inn-Spanish]; Bumetanide; Bumetanide [Usan:Ban:Inn:Jan]; Bumetanidum [Inn-Latin]; Bumex; Burine; Burinex; CHEMBANK404; EI-168; Fontego; Fordiuran; Lixil; Lunetoron; PF 1593; Segurex; [Inn-Spanish] | ||
| Indication | For the treatment of edema associated with congestive heart failure, hepatic and renal disease including the nephrotic syndrome | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | Bumetanide, a sulfonamide-type loop diuretic structurally related to furosemide, is used to manage hypertension and edema associated with congestive heart failure, cirrhosis, and renal disease, including the nephrotic syndrome. Bumetanide inhibits sodium reabsorption in the ascending limb of the loop of Henle. | ||
| Mechanism Of Action | Bumetanide interferes with renal cAMP and/or inhibits the sodium-potassium possibly sodium in the ascending loop of Henle, altering electrolyte transfer in the proximal tubule. This results in excretion of sodium, chloride, and water and, hence, leads to diuresis. | ||
| Bumetanide News (When available) |
Membrane trafficking and the regulation of NKCC2 Feb 9, 2006 Increased Serum Creatinine More Likely when Nesiritide is Combined ... Nov 16, 2005 Alternative renin regulatory pathways and the NKCC1 isoform Nov 8, 2005 An existing diuretic may suppress seizures in newborns 31 Oct 2005 Jan de Vries: Is there an alternative to taking steroids for life? Mar 14, 2005 Jan de Vries: Is there an alternative to taking steroids for life? 14 Mar 2005 | ||
| Dosage Forms | TABLET | ||
| Drug_Category | Diuretics; ATC:C03CA02 | ||
| Absorption | Not Available | ||
| Interactions |
Interactions for Bumetanide: 1. Drugs with ototoxic potential: Especially in the presence of impaired renal function, the use of parenterally administered bumetanide in patients to whom aminoglycoside antibiotics are also being given should be avoided, except in life-threatening conditions. 2. Drugs with nephrotoxic potential: There has been no experience on the concurrent use of bumetanide with drugs known to have a nephrotoxic potential. Therefore, the simultaneous administration of these drugs should be avoided. 3. Lithium: Lithium should generally not be given with diuretics (such as bumetanide) because they reduce its renal clearance and add a high risk of lithium toxicity. 4. Probenecid: Pretreatment with probenecid reduces both the natriuresis and hyperreninemia produced by bumetanide. This antagonistic effect of probenecid on bu-metanide natriuresis is not due to a direct action on sodium excretion but is probably secondary to its inhibitory effect on renal tubular secretion of bumetanide. Thus, probenecid should not be administered concurrently with bumetanide. 5. Indomethacin: Indomethacin blunts the increases in urine volume and sodium excretion seen during bumetanide treatment and inhibits the bumetanide-induced increase in plasma renin activity. Concurrent therapy with bumetanide is thus not recommended. 6. Antihypertensives: Bumetanide may potentiate the effect of various antihypertensive drugs, necessitating a reduction in the dosage of these drugs. 7. Digoxin: Interaction studies in humans have shown no effect on digoxin blood levels. 8. Anticoagulants: Interaction studies in humans have shown bumetanide to have no effect on warfarin metabolism or on plasma prothrombin activity. | ||
| Toxicity | Overdosage can lead to acute profound water loss, volume and electrolyte depletion, dehydration, reduction of blood volume and circulatory collapse with a possibility of vascular thrombosis and embolism. Electrolyte depletion may be manifested by weakness, dizziness, mental confusion, anorexia, lethargy, vomiting and cramps. Treatment consists of replacement of fluid and electrolyte losses by careful monitoring of the urine and electrolyte output and serum electrolyte levels. LD50=4624 mg/kg (mice, oral) | ||
| Organisms Affected | Humans and other mammals | ||
| Chemical IUPAC Name | 3-butylamino-4-phenoxy-5-sulfamoyl-benzoic acid | ||
| Chemical Formula | C17H20N2O5S | ||
| Molecular Weight | 364.417 g/mol | ||
| Smiles String | CCCCNC1=C(C(=CC(=C1)C(=O)O)S(=O)(=O)N)OC2=CC=CC=C2 | ||
| Melting Point | 230-231 °C | ||
| Water Solubility | >20 mg/mL (in base) | ||
| State | Solid | ||
| LogP/Hphobicity | 3.261 | ||
| Isoelectric Point | Not Available | ||
| Biotransformation | 45% is secreted unchanged. Urinary and biliary metabolites are formed by oxidation of the N-butyl side chain. | ||
| Half Life | 1 - 1.5 hours | ||
| Protein Binding [%] | 97% | ||
| RxList Link | RXlist | ||
| Sponsored links | |||
| Drug Reference |
http://www.drugs.com/cons/Bumetanide.html http://www.rxlist.com/cgi/generic2/bumetan.htm http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/bum1058.shtml http://www.pharmgkb.org/views/index.jsp?objId= | ||
| Drug Type | Approved Drug | ||
| Accession No | APRD00294 | ||
| CAS Registry Number | 28395-03-1 | ||
| KEGG Compound ID | C06859 | ||
| PubChem ID | SID:175984 | ||
| PharmGKB ID | PA448682 | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | 728284 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |